Pangea Bio
Pangea Bio discovers and develops nature-inspired medicines to treat neurological and neuropsychiatric disorders. The company uses AI and machine learning to mine natural chemical space and traditional human-use evidence to identify candidate small molecules, and applies biotechnology and preclinical pharmacology to advance lead programs. Its lead asset, OT-003, targets central nervous system indications and the company leverages mechanisms including TrkB activation to drive neuronal plasticity and neuroprotection. Pangea Bio positions its discovery platform for partnerships with biotechnology and pharmaceutical companies and plans Phase 1 studies for its lead program.
Pangea Bio
Pangea Bio discovers and develops nature-inspired medicines to treat neurological and neuropsychiatric disorders. The company uses AI and machine learning to mine natural chemical space and traditional human-use evidence to identify candidate small molecules, and applies biotechnology and preclinical pharmacology to advance lead programs. Its lead asset, OT-003, targets central nervous system indications and the company leverages mechanisms including TrkB activation to drive neuronal plasticity and neuroprotection. Pangea Bio positions its discovery platform for partnerships with biotechnology and pharmaceutical companies and plans Phase 1 studies for its lead program.